



Ref: Syn/CS/SE/IP/2023-24/Jan/09

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

January 25, 2024

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
--	--

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and nine months ended December 31, 2023. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to March 31, 2024.

The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,
Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Investor Presentation.



Investor Presentation

January 2024



Safe harbour



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



Contents

- 1** Operating Highlights
 - 2** Syngene – Putting Science to Work
 - 3** Syngene strengths
 - 4** Financials
 - 5** Shareholding and Share Information
- Appendix**

Syngene



1

Operating Highlights

Syngene



Q3 and 9 Months FY24 performance

Operating Highlights

- The third quarter was underpinned by positive performance in Development and Manufacturing Services as well as in the Dedicated Centers. Performance in Discovery Services was impacted by the slowdown in biotech funding
- In Manufacturing Services, the Company continued to make good progress on the long-term biologics manufacturing partnership with Zoetis.
- Syngene concluded the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd. Once operational, the acquisition will add 20,000 litres of biologics drug substance manufacturing capacity to Syngene's existing capabilities. It also includes a commercial scale, high speed, fill-finish unit, which is an essential capability for drug product manufacturing. The facility is expected to be operational in the second half of FY25, subject to regulatory approvals.
- In Discovery Services, the Company added an assay biology capability at the Hyderabad campus to complement the existing Drug Metabolism and Pharmacokinetics (DMPK) and Compound Management facilities

Updated guidance: Revenue growth for the full year around double digits on a constant currency basis compared to earlier guidance of mid teens growth

Q3 Financial Highlights

Revenue from Operations: 9% YoY

Total Revenue: Rs 8,828 Mn
Reported EBITDA: Rs 2,608 Mn
Profit After Tax*: Rs 1,145 Mn

EBITDA from operations margin 27%
Profit after Tax* margin 13%
PAT* 4% YoY

9 Months FY24 Financial Highlights

Revenue from Operations: 17% YoY

Total Revenue: Rs 26,462 Mn
Reported EBITDA: Rs 7,720 Mn
Profit After Tax*: Rs 3,299 Mn

EBITDA from operations margin 27%
PAT* 16% YoY

**before exceptional items*

2

Syngene – Putting Science to Work

Syngene



Partner in innovation: #Putting science to work

Who we are and what we do

We aim to be a world class partner delivering innovative scientific solutions for clients



We offer integrated solutions across research, development and manufacturing



Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals




Our team includes more than ~6,000 scientists out of total ~8,500+ headcount, operating across 3 state-of-the-art campuses located in India's leading life science hubs: Bangalore, Mangalore and Hyderabad



Established track record in discovery research and development for small and large molecules. Emerging presence in commercial manufacturing

Our journey so far



Key facts and figures



400+
active clients



13 out of top **15**
pharma companies are
clients



400+
patents
held with clients



World class infrastructure
3 campuses in Bangalore, Hyderabad and Mangalore
qualified to meet international standards



Rs. 45,589 Mn
(US\$567Mn*)
Gross Block of
Investments ^



Rs. 32,638 Mn
(US\$406Mn*)
FY23 Revenue



Rs. 4,644 Mn
(US\$58Mn*)
FY23 PAT



~8,500+ headcount
including ~6,000+
talented scientists



75%
energy from
renewable sources

All figures are as on March 31, 2023, unless otherwise specified. @ ca. Rs 80 /US\$

^Tangible and Intangible Assets

Syngene



Our strategic priorities



Research: Discovery Services

Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities



Research: Dedicated Centers

Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows



Operational Excellence

Focus on customer delivery through operational excellence



Development and Manufacturing Services – Small Molecules

Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions

Secure US FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects



Development and Manufacturing Services – Large Molecules

Drive an integrated approach for biologics development and manufacturing to provide a one-stop-shop capability from drug discovery to commercial manufacturing for biologics

Accelerate capacity build-up



People

Develop strong leaders and managers while offering all employees career-long learning opportunities






Environmental, Social and Governance (ESG)

Committed to Science-based targets and operate in a responsible and sustainable manner.




Our broad capabilities, spanning the value chain, facilitate integration and captures additional benefits for clients

Research business		Development and Manufacturing business	
Discovery Services	Dedicated R&D Centers	Development Services	Manufacturing Services
 <p>Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs</p> <p>SynVent - our proprietary platform for Integrated Drug Discovery</p> <p>SARchitect - our proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies</p>	 <p>Ring-fenced infrastructure for exclusive operations for an individual client</p> <p>Dedicated, multi-disciplinary team of scientists</p> <p>Access to entire Syngene ecosystem for specialist research and development operations</p>	 <p>Pre-clinical to clinical trials</p> <p>Drug substance and drug product development</p> <p>Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate</p> <p>cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules</p>	 <p>Manufacturing of small and large molecules for commercial supplies</p> <p>cGMP-compliant facilities</p> <p>State-of-the art API manufacturing and Biologics manufacturing facilities</p>

Sustained investment in skilled workforce and world class infrastructure: a catalyst for expanded client base and strong revenue growth



Strategic investments augment cash flows and EPS, driving consistent shareholder returns



3

Syngene strengths

Syngene



Syngene strengths

A global scale CRO/CDMO

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



Science in our DNA

- Located in 3 top India life science hubs: Bangalore, Mangalore and Hyderabad
- ~6000+ qualified scientists including ~500 PhDs (~6,000+ total headcount)
- Resilient supply chain management
- 2 Mn+ sq. ft. world-class R&D and manufacturing infrastructure

Solutions through innovation

- IP fully assigned to clients
- Track record of data management and security
- Over 400+ patent filings by clients recognizing Syngene scientists



Blue chip client list

- + 400+ active clients
- Partnering with large / mid-size / emerging biopharma and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors

Quality matters



- Fully digitized quality organization
- Strong compliance track record with global regulators
- US FDA, EMA and PMDA approved, GLP certified, AAALAC accredited facilities
- 78 client and regulator audits in the last financial year



Making a difference

- Partnerships have delivered numerous clinical candidates
- Delivery history for integrated CMC programs up to clinical trials and beyond

Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small molecules and biologics)




* Human Pharmacology Unit

Experienced workforce: building capabilities and careers

~8,500+
total headcount

6000+ scientists delivering high quality solutions – create a competitive edge

■ PhDs ■ Master's Degree ■ Others



All figures are as on March 31, 2023



Inspiring technical excellence and providing opportunities to grow

Nurturing young talent and enhancing science skills

- Syngene Training Academy offers new graduate recruits a six-month extended induction to help them understand the Company's vision and values while acquiring the skills to be an industrial scientist
- Science Certification Program is open to all employees to enhance their capabilities keep their skills up to date and provide opportunities for continuous learning

Developing leaders and managers

- Emerging Leaders Development Program is designed to help strong managers transition from managerial to leadership roles
- Manager Development Program is designed for first- and second-line managers to develop basic management skills and performance management to help them manage their teams and ensure that they are making a positive contribution to the organizational goals

Promoting workplace diversity

- The Company has strong equal opportunity policies to protect against all forms of discrimination and provide a workplace where all employees can deliver their best work
- Support provided to parents of young families. 28% of our workforce are female and 20% of senior management positions are held by females

Extended our state-of-the-art infrastructure & new capabilities in different locations within India to meet our strategic partners needs...

HQ campus at Bangalore, India

90 Acres (3,64,217 sq. mt) where most of Syngene's capabilities are housed today



Biologics
Discovery development & and 2x manufacturing plants in Bangalore, India

Fully functional R&D Centre at
Genome Valley, Hyderabad, India



API manufacturing
Commercial manufacturing to support product launch located at Mangalore, India

We currently operate a range of successful collaboration models



Dedicated R&D Labs

- Dedicated scientific and support personnel customized and managed to partner requirements
- Dedicated infrastructure implemented and maintained by Syngene based upon partner specifications
- Access to additional R&D, Manufacturing and support functions at Syngene
- Long-term (5-7 years) contractual commitment



Full time equivalent (FTE)

- Dedicated scientific resources selected from partner-specified disciplines
- Deliverables and team composition evolve as project advances
- Typically ~3 year contract term ensures team continuity, adjustable with specified notice period
- Effective for longer-term research commitments



Fee For service (FFS)

- Flexible, on-demand resources with targeted skill sets
- Clearly defined project, limited in scope and deliverables
- Effective way to managed fluctuating demand, ad-hoc requests or uncertain quantity of work



Risk-reward

- Rewards based on clearly defined, pre-agreed milestones
- Project scope spans drug discovery, product development or truly end to end across both

... and are open to any single or combination of above

Our experience spans multiple industry segments and partners us with global leaders across the world...

Industry Segment	Partner Companies
Large & Mid-Sized BioPharma	Bristol Myers Squibb, GSK, sanofi, NOVARTIS, AMGEN, MERCK, Boehringer Ingelheim, Baxter
Emerging BioPharma (EBP)	Albireo (AN IPSEN COMPANY), AMPHISTA THERAPEUTICS, idorsia, Genmab, ASCENEURON, PharmAust LIMITED, saniona, C4 Therapeutics
Animal Health	zoetis, Elanco, MERCK, BAYER
AgroChem	FMC, Dow, Dow AgroSciences
CPG	Givaudan, PURINA, Unilever
Chemicals/Polymers	BAUSCH+LOMB, essilor, Beiersdorf, KRATON

Operational robustness driving strategy execution

Continuous improvement embedded in operations driven by certified operational leaders

Six Sigma Black Belt certified staff in each service line and support function
Green belt certified staff across operations
All employees white belt certified

Quality management system: digitized and audit-ready

80 customer and regulator audits in the last financial year
8 successful USFDA audits in the last 4 years

Client-focused commercial organization

Leaders based in the US, Europe, UK and Asia
Close to client locations



Focused execution through strong Project Management

Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects

Digital as a differentiator

AI capability in all research teams
IoT for maintenance and infrastructure reliability
Data Management, IT infrastructure and security systems to strengthen our proposition as a strategic partner to clients


Strategic Sourcing that makes a difference

Strategic supplier management to avoid supply chain disruption
Supply distributed across the world to ensure business continuity

We are harnessing digitization and automation through our Lab 4.0 strategy

At Syngene, we have adopted Lab 4.0, deploying technology for compliance, as an optimizer and as an augments

Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements



Committed to safety and sustainability

Safety is our first priority

- Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
- Risk assessments are an integral part of our operation: a proactive approach in incident prevention
- Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
- Lost time injury frequency rate (LTIFR): 0.08
- 69,280 hours of EHSS training



Committed to environmental protection

- Committed to Science-based targets for greenhouse gases
- 90+% of total hazardous and non-hazardous waste recycled
- 75% of energy procured from green energy sources
- 3.8% YoY reduction in energy usage
- 2683 MT equivalent CO2 savings from energy conservation
- 52834 MT equivalent CO2 savings from green power.
- 40% YoY freshwater savings achieved
- 71389 KL fresh water saved from recycling, reusing and rainwater harvesting.
- 1021 KL water rainwater harvested

Refer to the [CSR link](#) on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development
Refer to the [ESG Report](#) on our website to know more

International accreditations



- USFDA, OHSAS 18001
- GLP, cGMP, AAALAC & CPCSEA Certified facilities
- CAP accreditation, ISO/IEC 27001:2013 accreditation
- EMA and PMDA approved, AAALAC accredited facility
- The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL)



We have consistently received industry recognition for our scientific capability and business excellence

- **CMO Leadership Award Winner 2020** - under Categories: Capabilities, Compatibility, Expertise and Service
- Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia—Viral Clearance and Safety Testing'
- **Great Place to Work Certified™ Company (ASSOCHAM) CSR & NGO Awards 2020** for our contribution to COVID-19 relief work in Karnataka.
- **CMO Leadership Awards 2022** Presented by Life Science Leader and Outsourced Pharma
- **CMO Leadership Award Champion 2022** - Presented by Life Science Leader and Outsourced Pharma
- **Golden Peacock Award for Excellence in Corporate Governance** for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Unique or Innovative Leadership Program'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Advance in Compliance Training'
- **Asia Pacific Biologics CMO Excellence Awards 2022** - For Quality
- **Biopharma Honours Award 2022** - For Viral Testing Facility by Informa Markets
- **Most Preferred Workplace 2022** - Award by MarksmenDaily.com
- **Golden Peacock National Quality Award 2023** For meeting the overall requirements of the Golden Peacock Excellence Model
- **Biopharma Excellence Awards 2023** For Best Contract Development and Manufacturing Organization (CDMO)

2019

2020

2021

2022

2023

9M 2024


- 
- Ranked as one of the **25 fastest growing companies in India** by Outlook Business
 - **CMO Leadership Awards 2019** - Presented by Life Science Leader Magazine
 - **FICCI CSR Award for Environmental Sustainability** - At the 17th Edition of the awards in New Delhi
 - **Safe Workplace Champion Award** - At the 8th Manufacturing Supply Chain Summit and Awards
 - **Best Leadership Development Program for Middle Management Award** - At the 6th Global Training and Development Leadership Awards
 - **India Pharma Award 2019** - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo.
 - **Utthama Suraksha Puraskar 2019** - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma** - for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence—Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Most Innovative New Learning Programme** at the L&D Vision & Innovation Award organized by Transformation Forums
- **Mahatma Award 2021** under Health & Wellbeing Category
- **Best Corporate Foundation Award** at the World CSR Congress

- **Golden Peacock Award 2023:** For risk management practices under the Pharmaceutical sector category.
- Awarded **India Best Managed Company** by Deloitte
- **Kaizen Excellence Awards;** Won four gold awards at QCFL under different categories
- **Supply Chain Champion Award, 2023** : Winner in the ISCM Supply Chain Ranking in the pharmaceutical sector
- **Best Overall Sustainable Performance (Pharmaceutical) 2023** at the 2nd Edition India Sustainability Conclave & Awards 2023
- Excelled at **CI National Six Sigma Competition** winning 4 Platinum awards.

Robust risk management framework

Syngene has a risk management framework to identify, monitor, report and manage risk
 Every risk owner monitors and manages risks relevant to their area of responsibility



Refer [Annual report](#) for complete risk profile and risk mitigation strategy

4

Financials



Q3FY24 financial highlights

Particulars	Q3 FY24	Q3 FY23	YoY change	Q2 FY24	QoQ change
Revenue from operations	8,535	7,859	9%	9,101	-6%
Other income	293	172	70%	216	35%
Reported revenue	8,828	8,031	10%	9,317	-5%
Material costs	2,374	2,061	15%	2,672	-11%
Staff costs	2,405	2,192	10%	2,412	0%
Other direct costs	254	264	-4%	275	-8%
Other expenses	1,063	876	21%	1,022	4%
Foreign exchange (gain)/loss, net	124	156	-21%	179	-31%
EBITDA	2,608	2,482	5%	2,757	-5%
EBITDA Margin	30%	31%		30%	
Depreciation and Finance Cost	1,189	1,083	10%	1,176	1%
PBT	1,419	1,399	1%	1,581	-10%
Tax	274	302	-9%	361	-24%
PAT before exceptional items	1,145	1,097	4%	1,220	-6%
PAT Margin	13%	14%		13%	
PAT after exceptional items*	1,115	1,097	2%	1,167	-4%

*(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)

(1) Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less (Trade payables + Others current liabilities) at the end of the year

(2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

Syngene

All figures in Rs. Mn unless otherwise specified

Balance Sheet Highlights

As on 31st December 2023

Shareholders' funds	40,284
Net Fixed assets	37,152
Other net assets ⁽¹⁾	-842
Net cash/(debt) ⁽²⁾	3,974
Total Use of Funds	40,284

9MFY24 financial highlights

Particulars	9M FY24	9M FY23	YoY change
Revenue from operations	25,717	21,985	17%
Other income	745	481	55%
Reported revenue	26,462	22,466	18%
Material costs	7,274	5,664	28%
Staff costs	7,105	6,347	12%
Other direct costs	805	835	-4%
Other expenses	3,100	2,561	21%
Foreign exchange (gain)/loss, net	458	376	22%
EBITDA	7,720	6,682	16%
EBITDA Margin	29%	30%	
Depreciation and Finance Cost	3,491	3,055	14%
PBT	4,229	3,627	17%
Tax	930	771	21%
PAT before exceptional items	3,299	2,856	16%
PAT Margin	12%	13%	
PAT after exceptional items*	3,214	2,856	13%

All figures in Rs. Mn unless otherwise specified

5

Shareholding and Share Information



Syngene and Biocon Group

Syngene

Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. Company has 25+ years of experience in novel molecule discovery, development and manufacturing services




Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene



Syngene

Integrated services:

- Discovery research
- Development
- Manufacturing small/large molecules




- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs



Biocon*

Shareholding and Share Information

Syngene's Shareholding Pattern*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Mn)	2,81,993
% free-float	45%
Free-float market cap (Rs. Mn)	1,26,897
Share Outstanding (Mn)	402

For more details

Visit our website www.syngeneintl.com



<https://twitter.com/SyngeneIntl>



<https://www.linkedin.com/company/syngene-international-limited>



<https://www.facebook.com/syngeneintl/>



<https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ>

IR Contact:

Krishnan G/ Suruchi Daga

+ 91 9819992927/+91 8800176009

investor@syngeneintl.com

krishnan.g@syngeneintl.com

suruchi.daga@syngeneintl.com

Media Contact:

Shotorupa Ghosh

+91 8450977080

shotorupa.ghosh@syngeneintl.com





Syngene

Putting Science to Work

Thank you

© 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document.

www.syngeneintl.com

Stay Connected

